RESUMEN
Genetic testing is becoming rapidly more accessible to the general populous either through or outside healthcare systems. Few large-scale studies have been carried out to gauge public opinion in this growing area. Here, we undertook the largest cross-sectional study on genetic testing in the UK. The primary purpose of this study is to identify the differences in attitudes toward genetic testing across ethnic groups. A cohort of 6500 individuals from a diverse population completed a 72-item survey in a cross-sectional study. Responses between ethnic minority and white individuals in the UK were compared using a wilcoxon rank-sum and chi-square tests. The white cohort was approximately twice as likely to have taken a genetic test and 13% more had heard about genetic testing before the survey. The ethnic minority cohort appeared more apprehensive about the impact of genetic testing on employability. This study highlights that in the UK, significant differences in opinions regarding genetic testing exist between white individuals and ethnic minority individuals. There is an urgent need to develop more inclusive strategies to equally inform individuals from all backgrounds to avoid disparities in the utilisation of genetic testing.
Asunto(s)
Etnicidad , Opinión Pública , Humanos , Etnicidad/genética , Estudios Transversales , Grupos Minoritarios , Pruebas Genéticas , Reino UnidoRESUMEN
BACKGROUND: Genital tract infections caused by Neisseria gonorrhoeae are a major cause of sexually transmitted disease worldwide. Surveillance data suggest that incidence has increased in recent years after initially falling in the face of intensified control efforts. OBJECTIVES: The authors sought to evaluate the potential contribution of antimicrobial resistance to such rebound and to identify optimal treatment strategies in the face of resistance using a mathematical model of gonorrhoea. METHODS: The authors built risk-structured 'susceptible-infectious-susceptible' models with and without the possibility of antibiotic resistance and used these models as a platform for the evaluation of competing plausible treatment strategies, including changing antimicrobial choice when resistance prevalence surpassed fixed thresholds, random assignment of treatment and use of combination antimicrobial therapy. RESULTS: Absent antimicrobial resistance, strategies that focus on treatment of highest risk individuals (the so-called core group) result in collapse of disease transmission. When antimicrobial resistance exists, a focus on the core group causes rebound in incidence, with maximal dissemination of antibiotic resistance. Random assignment of antimicrobial treatment class outperformed the use of fixed resistance thresholds with respect to sustained reduction in gonorrhoea prevalence. CONCLUSIONS: Gonorrhoea control is achievable only when core groups are treated, but treatment of core groups maximises dissemination of antimicrobial-resistant strains. This paradox poses a great dilemma to the control and prevention of gonorrhoea and underlines the need for gonococcal vaccines.
Asunto(s)
Antibacterianos/farmacología , Farmacorresistencia Bacteriana , Gonorrea/epidemiología , Gonorrea/microbiología , Neisseria gonorrhoeae/efectos de los fármacos , Neisseria gonorrhoeae/aislamiento & purificación , Antibacterianos/uso terapéutico , Control de Enfermedades Transmisibles/métodos , Gonorrea/tratamiento farmacológico , Gonorrea/prevención & control , Humanos , Modelos Teóricos , América del Norte/epidemiología , PrevalenciaRESUMEN
OBJECTIVES: Herpes simplex virus (HSV) infections in newborns are an uncommon but potentially devastating consequence of genital HSV infection in women. Current practice focuses on preventing perinatal transmission by women with prevalent HSV, but transmission risk is greatest when genital HSV is acquired for the first time late in pregnancy. The objective of this study was to assess the effectiveness and cost effectiveness of identifying pregnant women at risk of de novo HSV acquisition as a means of preventing vertical HSV transmission. METHODS: A Bayesian decision tree model was parameterized using the best available health and economic data relating to HSV in pregnancy and was used to evaluate the cost effectiveness of screening to identify individuals susceptible to HSV infection in a hypothetical cohort of 100,000 pregnant women in their second trimester of pregnancy. Final outcomes were the projected incidence of maternal and neonatal HSV, quality-adjusted life expectancy and life-time costs associated with neonatal HSV. RESULTS: In the absence of testing, model projected incidence of neonatal HSV was 34 cases per 100,000 births, similar to available surveillance data. Screening pregnant women and their partners was projected to decrease the incidence of HSV-1 and HSV-2 infections in women and infants and to save costs. These findings were robust under alternative assumptions and in wide-ranging sensitivity analyses. CONCLUSIONS: The use of accurate and relatively inexpensive serological tests for HSV to identify women vulnerable to incident HSV infection in pregnancy has the potential to reduce neonatal HSV incidence and reduce health-related costs.
Asunto(s)
Herpes Simple/diagnóstico , Complicaciones Infecciosas del Embarazo/diagnóstico , Diagnóstico Prenatal/economía , Teorema de Bayes , Ahorro de Costo , Análisis Costo-Beneficio , Diagnóstico Precoz , Femenino , Herpes Simple/economía , Herpesvirus Humano 1 , Herpesvirus Humano 2 , Humanos , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Embarazo , Complicaciones Infecciosas del Embarazo/economía , Resultado del Embarazo , Tercer Trimestre del Embarazo , Años de Vida Ajustados por Calidad de Vida , Parejas SexualesRESUMEN
BACKGROUND: In HIV-infected pregnant women, viral suppression prevents mother-to-child HIV transmission. Directly observed highly-active antiretroviral therapy (HAART) enhances virological suppression, and could prevent transmission. Our objective was to project the effectiveness and cost-effectiveness of directly observed administration of antiretroviral drugs in pregnancy. METHODS AND FINDINGS: A mathematical model was created to simulate cohorts of one million asymptomatic HIV-infected pregnant women on HAART, with women randomly assigned self-administered or directly observed antiretroviral therapy (DOT), or no HAART, in a series of Monte Carlo simulations. Our primary outcome was the quality-adjusted life expectancy in years (QALY) of infants born to HIV-infected women, with the rates of Caesarean section and HIV-transmission after DOT use as intermediate outcomes. Both self-administered HAART and DOT were associated with decreased costs and increased life-expectancy relative to no HAART. The use of DOT was associated with a relative risk of HIV transmission of 0.39 relative to conventional HAART; was highly cost-effective in the cohort as a whole (cost-utility ratio $14,233 per QALY); and was cost-saving in women whose viral loads on self-administered HAART would have exceeded 1000 copies/ml. Results were stable in wide-ranging sensitivity analyses, with directly observed therapy cost-saving or highly cost-effective in almost all cases. CONCLUSIONS: Based on the best available data, programs that optimize adherence to HAART through direct observation in pregnancy have the potential to diminish mother-to-child HIV transmission in a highly cost-effective manner. Targeted use of DOT in pregnant women with high viral loads, who could otherwise receive self-administered HAART would be a cost-saving intervention. These projections should be tested with randomized clinical trials.
Asunto(s)
Terapia Antirretroviral Altamente Activa/economía , Terapia por Observación Directa , Infecciones por VIH/tratamiento farmacológico , Complicaciones Infecciosas del Embarazo/tratamiento farmacológico , Tercer Trimestre del Embarazo , Terapia Antirretroviral Altamente Activa/métodos , Simulación por Computador , Análisis Costo-Beneficio , Femenino , Humanos , Recién Nacido , Transmisión Vertical de Enfermedad Infecciosa/prevención & control , Esperanza de Vida , Modelos Teóricos , Embarazo , Complicaciones Infecciosas del Embarazo/economía , Ensayos Clínicos Controlados Aleatorios como Asunto , Carga ViralRESUMEN
BACKGROUND: Community-acquired pneumonia (CAP) is a major cause of morbidity and mortality worldwide. Clinical practice guidelines for empirical CAP treatment, formulated jointly by the Infectious Diseases Society of America (IDSA) and American Thoracic Society (ATS), remain controversial and inconsistently applied. We evaluated the impact of guideline-concordant therapy on in-hospital survival and other outcomes using a large database including adults treated for CAP in both community and tertiary care hospitals. METHODS: We evaluated the association between in-hospital survival and guideline-concordant therapy using logistic regression models. Time until discharge from hospital and discontinuation of parenteral therapy were evaluated using survival analysis. RESULTS: Of 54 619 non-intensive care unit inpatients with CAP hospitalized at 113 community hospitals and tertiary care centers, 35 477 (65%) received initial guideline-concordant therapy. After adjustment for severity of illness and other confounders, guideline-concordant therapy was associated with decreased in-hospital mortality (odds ratio [OR], 0.70; 95% confidence interval [CI], 0.63-0.77), sepsis (OR, 0.83; 95% CI, 0.72-0.96), and renal failure (OR, 0.79; 95% CI, 0.67-0.94), and reduced both length of stay and duration of parenteral therapy by approximately 0.6 days (P < .001 for both comparisons). These findings were robust with alternate definitions of "concordance" and were linked to treatment with fluoroquinolone or macrolide agents. CONCLUSIONS: Guideline-concordant therapy for CAP is associated with improved health outcomes and diminished resource use in adults. The mechanisms underlying this finding remain speculative and warrant further study, but our findings nonetheless support compliance with CAP clinical practice guidelines as a benchmark of quality of care.